Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Lobular | 2 | 2020 | 26 | 0.820 |
Why?
|
| Breast Neoplasms | 5 | 2024 | 1207 | 0.710 |
Why?
|
| Breast Carcinoma In Situ | 1 | 2020 | 3 | 0.680 |
Why?
|
| Carcinoma in Situ | 1 | 2020 | 35 | 0.660 |
Why?
|
| Dietary Supplements | 2 | 2024 | 235 | 0.310 |
Why?
|
| Chemoprevention | 1 | 2024 | 42 | 0.220 |
Why?
|
| Breast Density | 1 | 2024 | 17 | 0.220 |
Why?
|
| Cholecalciferol | 1 | 2024 | 28 | 0.220 |
Why?
|
| Premenopause | 2 | 2024 | 60 | 0.210 |
Why?
|
| Hyperplasia | 2 | 2020 | 88 | 0.200 |
Why?
|
| Dendritic Cells | 3 | 2012 | 525 | 0.200 |
Why?
|
| Bevacizumab | 1 | 2022 | 59 | 0.190 |
Why?
|
| Vitamin D | 2 | 2024 | 140 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 863 | 0.180 |
Why?
|
| Mammography | 1 | 2024 | 291 | 0.180 |
Why?
|
| Neoplasms | 2 | 2022 | 1370 | 0.180 |
Why?
|
| Qualitative Research | 1 | 2024 | 697 | 0.160 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2019 | 45 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 447 | 0.150 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2018 | 2 | 0.150 |
Why?
|
| Breast | 1 | 2020 | 187 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2012 | 212 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 661 | 0.140 |
Why?
|
| Mucin-1 | 3 | 2012 | 14 | 0.140 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1258 | 0.130 |
Why?
|
| Uridine | 1 | 2016 | 22 | 0.130 |
Why?
|
| Anus Neoplasms | 1 | 2016 | 25 | 0.130 |
Why?
|
| Acetates | 1 | 2016 | 33 | 0.130 |
Why?
|
| Fluorouracil | 1 | 2016 | 66 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 42 | 0.130 |
Why?
|
| Cancer Vaccines | 2 | 2012 | 49 | 0.110 |
Why?
|
| Ovarian Neoplasms | 2 | 2013 | 150 | 0.110 |
Why?
|
| Biomarkers | 1 | 2019 | 1410 | 0.100 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2013 | 7 | 0.100 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2013 | 3 | 0.100 |
Why?
|
| Obesity | 1 | 2021 | 1234 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2013 | 69 | 0.100 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2012 | 33 | 0.100 |
Why?
|
| Th17 Cells | 1 | 2012 | 61 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 140 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2012 | 181 | 0.090 |
Why?
|
| Humans | 13 | 2024 | 63579 | 0.090 |
Why?
|
| Female | 7 | 2024 | 32989 | 0.090 |
Why?
|
| Granzymes | 1 | 2010 | 21 | 0.080 |
Why?
|
| Antigens, Differentiation | 1 | 2010 | 138 | 0.080 |
Why?
|
| Quinazolines | 1 | 2009 | 22 | 0.080 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2009 | 14 | 0.080 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 33 | 0.080 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 669 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2010 | 347 | 0.070 |
Why?
|
| CD3 Complex | 1 | 2008 | 65 | 0.070 |
Why?
|
| CD28 Antigens | 1 | 2008 | 60 | 0.070 |
Why?
|
| Interleukin-12 | 1 | 2008 | 128 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 347 | 0.070 |
Why?
|
| Oligonucleotides | 1 | 2008 | 221 | 0.060 |
Why?
|
| Middle Aged | 5 | 2024 | 17693 | 0.060 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 200 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 1007 | 0.060 |
Why?
|
| Lymphocyte Activation | 3 | 2012 | 758 | 0.050 |
Why?
|
| Adult | 4 | 2024 | 16884 | 0.050 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2022 | 19 | 0.050 |
Why?
|
| Carboplatin | 1 | 2022 | 43 | 0.050 |
Why?
|
| Decision Support Techniques | 1 | 2024 | 197 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2464 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2024 | 523 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2022 | 101 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2024 | 2080 | 0.040 |
Why?
|
| Internet | 1 | 2024 | 470 | 0.040 |
Why?
|
| Prognosis | 2 | 2019 | 1748 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2019 | 11 | 0.040 |
Why?
|
| Cell Fusion | 2 | 2010 | 37 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2019 | 85 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2019 | 738 | 0.030 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 2016 | 3 | 0.030 |
Why?
|
| Mucositis | 1 | 2016 | 8 | 0.030 |
Why?
|
| Antidotes | 1 | 2016 | 21 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 237 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2012 | 2155 | 0.030 |
Why?
|
| Fatigue | 1 | 2016 | 112 | 0.030 |
Why?
|
| Male | 3 | 2024 | 29977 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2010 | 985 | 0.030 |
Why?
|
| Neutrophils | 1 | 2016 | 376 | 0.030 |
Why?
|
| Taxoids | 1 | 2013 | 26 | 0.020 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 39 | 0.020 |
Why?
|
| Th1-Th2 Balance | 1 | 2012 | 3 | 0.020 |
Why?
|
| Fowlpox virus | 1 | 2012 | 4 | 0.020 |
Why?
|
| STAT Transcription Factors | 1 | 2012 | 17 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 25 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2012 | 14 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 277 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 190 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 280 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 128 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2012 | 149 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2013 | 158 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 453 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 238 | 0.020 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2010 | 9 | 0.020 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2009 | 4 | 0.020 |
Why?
|
| Clone Cells | 1 | 2010 | 114 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2009 | 40 | 0.020 |
Why?
|
| Peritoneal Neoplasms | 1 | 2009 | 28 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2010 | 148 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 507 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 244 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 299 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 3769 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 5363 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 1470 | 0.020 |
Why?
|
| Receptors, CCR7 | 1 | 2008 | 9 | 0.020 |
Why?
|
| Cytokines | 1 | 2012 | 934 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2009 | 370 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 585 | 0.020 |
Why?
|
| Mutation | 1 | 2016 | 2611 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2010 | 237 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2010 | 567 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 863 | 0.020 |
Why?
|
| Antibodies | 1 | 2008 | 182 | 0.020 |
Why?
|
| Aged | 2 | 2016 | 14504 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2008 | 160 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2012 | 879 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 2195 | 0.010 |
Why?
|
| Phenotype | 1 | 2008 | 1206 | 0.010 |
Why?
|
| Protein Binding | 1 | 2008 | 1602 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2008 | 1350 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 10843 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2009 | 5701 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 20678 | 0.010 |
Why?
|